News & Views
Shonin Approval for ProBeam System
May 12 2017 Read 802 Times
Varian Medical Systems has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam® system for proton therapy in Japan. The system was also showcased at the Particle Therapy Co-Operative Group (PTCOG), May 11-13, 2017 in Yokohama, Japan.
The system’s pencil beam scanning technology allows clinicians to deliver more precise doses inside the tumour thus reducing risk to nearby healthy tissue. When combined with cone beam computed tomography (CBCT), the ProBeam also enables advanced image-guided adaptive therapy during the course of treatment helping to make it the most precise form of proton therapy available.
Because the proton beams can be controlled so that they deposit their energy within the tumour site rather than passing all the way through the patient the treatment is particularly suitable for pediatric cancer cases as well as for adults.
"We are very pleased that the ProBeam system has now received Shonin approval," said Moataz Karmalawy, general manager of Varian's Particle Therapy division. "This approval is an important step in the growing availability of proton therapy in Japan and around the world."
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Jan 29 2020 Ghent, Belgium
Feb 03 2020 Dubai, UAE